Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48.

Article  CAS  PubMed  Google Scholar 

Cisneros-Villanueva M, Hidalgo-Pérez L, Rios-Romero M, Cedro-Tanda A, Ruiz-Villavicencio CA, Page K, et al. Cell-free DNA analysis in current cancer clinical trials: a review. Br J Cancer. 2022;126:391–400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaudhuri AA, Pellini B, Pejovic N, Chauhan PS, Harris PK, Szymanski JJ, et al. Emerging roles of urine-based tumor DNA analysis in bladder cancer management. JCO Precis Oncol. 2020;4:PO.20.00060.

PubMed  PubMed Central  Google Scholar 

Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, et al. Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023;20:406–19.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17:259–70.

Article  PubMed  PubMed Central  Google Scholar 

Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, et al. Bladder cancer. The Lancet. 2016;388:2796–810.

Article  Google Scholar 

Maas M, Todenhöfer T, Black PC. Urine biomarkers in bladder cancer — current status and future perspectives. Nat Rev Urol. 2023;20:597–614.

Article  PubMed  Google Scholar 

Linscott JA, Meeks JJ, Dyrskjøt L, Li R. The elusive horizon: biomarkers in urothelial carcinoma. Eur Urol. 2024;85:317–9.

Article  CAS  PubMed  Google Scholar 

Bao Y, Zhang D, Guo H, Ma W. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Sci. 2024;115:1060–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van’t Veer LJ, MJM M. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22:15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24:766–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.

Article  CAS  PubMed  Google Scholar 

Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124:345–58.

Article  PubMed  Google Scholar 

Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, et al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death Dis. 2019;10:1–11.

Article  Google Scholar 

Kamat AA, Bischoff FZ, Dang D, Baldwin M, Han LY, Lin YG, et al. Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma. Cancer Biology & Therapy. 2006;5:1369–74.

Article  CAS  Google Scholar 

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24–4.

Article  PubMed  PubMed Central  Google Scholar 

Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, et al. Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: a critical review of current literature. Eur Urol Oncol. 2021;4:893–903.

Article  PubMed  Google Scholar 

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.

Article  CAS  PubMed  Google Scholar 

Yao W, Mei C, Nan X, Hui L. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study. Gene. 2016;590:142–8.

Article  CAS  PubMed  Google Scholar 

Kim H, Park KU. Clinical circulating tumor DNA testing for precision oncology. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 2023;55:351.

Article  CAS  Google Scholar 

Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67–71.

CAS  PubMed  Google Scholar 

Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res. 1999;5:2689–92.

CAS  PubMed  Google Scholar 

Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 2002;100:542–8.

Article  CAS  PubMed  Google Scholar 

Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100:8817–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica. 2016;101:830–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.

Article  PubMed  PubMed Central  Google Scholar 

Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, et al. Target-enrichment strategies for next-generation sequencing. Nat Methods. 2010;7:111–8.

Article  CAS  PubMed  Google Scholar 

Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, et al. Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer. Clin Cancer Res. 2023;29:1719–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547–55.

Article  CAS  PubMed  PubMed Central